Introduction {#S1}
============

β-thalassemia is one of the most common monogenic disorder in the world. The incidence of this disease is high in many parts of the Indian subcontinent.^[@R1]^ There are 29.7 million carriers of β-thalassemia while approximately 7000 affected infants are born every year.^[@R2]^ More than 200 disease causing mutations have been described to date.^[@R3]^ There are five major and many rare β-thalassemia mutations seen in Asian Indians.^[@R4]--[@R9]^ The human β-globin protein of 146 amino acids is encoded by the globin gene with 3 exons (coding regions) with two major non-coding (introns) specified as intervening sequences IVS 1 and IVS 2. Two major mutations are IVS 1.5 (G→C) and IVS 1.1 (G→T), lying on the IVS 1 intron; the former being the most common mutation in India.^[@R1],[@R10],[@R11]^ One of the deletion mutations (619 bp deletion) lies on the IVS 2 intron. The other prevalent mutations are Cd8/9 (+G frameshift mutation), HbE (Cd 26 G→A) on the first exon and Cd41/42 (-TCTT) on the second exon. Five major and many rare mutations have been characterized in various states of India, *e.g.* West Bengal, Haryana, Punjab, Uttar Pradesh, Bihar, Orissa.^[@R1],[@R7],[@R8]^ Thalassemia is characterized by hemolytic anemia with dependence on regular blood transfusions for survival.^[@R12]^

About 62% of the present study population is native tribal (<http://www.mrcindia.org/rourkela.htm>) and the rest migrant from adjoining districts.^[@R13]^ The study area is hyperendemic to malaria and also known for a prevalence of sickle hemoglobin.^[@R14],[@R15]^ This supports the theory of evolution of hemoglobinopathies and thalassemic mutations along with malaria and their co-existence in the human gene pool,^[@R16]^ which may influence the overall genetic make-up of mutations inherited in the course of evolution. Furthermore, there is dearth of hospital based reports from this area concerning β-thalassemic gene mutations correlated with clinical severity. The classical β-thalassemia phenotypes can be modified by a number of environmental and genetic interacting factors,^[@R13]^ and, therefore, the genotype-phenotype relationship plays an important role in studying clinical severity. The present study deals with characterization of β-thalassemic gene mutations, which remain uncharacterized in this part of India, and also the genotype-phenotype correlations from western Orissa.

Materials and Methods {#S2}
=====================

Study area and ethical approval
-------------------------------

The study site was Rourkela, a city of western Orissa (Eastern India) situated at an average altitude of 200 m (21°35\'-22°35\'N, 83°32\'-85°22\'E). The Institutional Review Board, Ispat General Hospital, Rourkela, Orissa, India, approved this study and the Informed Consent Form (ICF) that was designed for this study.

Clinical history and examination
--------------------------------

A total of 38 subjects were enrolled (age 6 months-41years, median age 8 years. There were 22 males and 16 females. A complete clinical history was recorded along with blood transfusion events. Patients were examined for organomegaly and growth parameters. Family history of any hemoglobinopathies, thalassemia, mortality due to such genetic disorders, etc., was recorded.

Sample collection
-----------------

After obtaining written consent on the ICF from each individual or parents of individuals under the age of 18 years, 3 mL of venous blood was drawn from each subject and stored in pretreated EDTA (ethylene-diamine-tetra-acetic acid) tubes, 1 mL of which was used for genomic DNA isolation and 2 mL for hemoglobin electrophoresis and estimation of complete blood count.

Mutational analysis by amplification refractory mutation system polymerase chain reaction
-----------------------------------------------------------------------------------------

Genomic DNA was extracted using a commercial kit (Qiagen, Germany) according to the manufacturer\'s instructions. An ARMS (Amplification Refractory Mutation System) polymerase chain reaction (PCR) protocol was followed to detect any mutation as described by Old *et al.*^[@R8]^ Fragments were separated in ethidium bromide stained agarose gels and results were documented in a Gel Documentation system with DOC it-LS software (UVT, UK). PCR assays were reproduced at least twice within a period of 15 days for confirmation.

Hemoglobin electrophoresis
--------------------------

Hemoglobin electrophoresis was carried out in an automated electrophoresis system (Sebia, France) according to the manufacturer\'s instructions and fractions were analyzed using Phoresis software version 4.8.9 (Sebia, France). Standard sickle cell trait sample (with hemoglobin A, sickle cell hemoglobin, fetal hemoglobin and hemoglobin A~2~ fractions) accompanied with each run served as a positive control.

Data analysis
-------------

Single band for PCR assays with mutant primers was concluded as pure mutant (homozygous) whereas presence of bands in both wild-type and mutant PCR assay was inferred as a heterozygous mutant for the particular mutation concerned. Frequency distribution was calculated and comparisons were made in Excel spreadsheets (Microsoft).

Results {#S3}
=======

Genotypic data
--------------

In the present study, 38 individuals aged 6 months to 41 years were enrolled to study the characteristics of β-thalassemia mutations in Western Orissa, India, and also the genotype-phenotype correlation. IVS 1.5 mutation was the predominant form in 24 (63.1%) samples; 14 (36.8%) of these were heterozygous mutant and 10 (26.3%) were homozygous mutant alleles. The major associated hemoglobinopathy was sickle cell hemoglobin (HbS) with 8 patients as sickle β^0^ thalassemia and 4 were sickle β^+^ thalassemia. Distribution of other major mutations can be seen in [Figure 1](#F1){ref-type="fig"}A. Size of mutant alleles obtained corresponding to the mutations ranged from 234--488 bp ([Table 1](#T1){ref-type="table"}).

Figure 1A) Frequency distribution of β-thalassemia mutant alleles, total mutant (white bars), heterozygous mutants (black bars) and homozygous mutants (gray bars); B) analysis of wild and mutant β-thalassemia alleles by polymerase chain reaction-amplification refractory mutation system assay. Each pair of gel pictures corresponds to the respective wild (W) and mutant (M) alleles detected by polymerase chain reaction-amplification refractory mutation system.

Table 1Analysis of fragment length of β-thalassemia mutant alleles.N.Mutation typeAllele length in nucleotide base pairs1IVS 1.1488^[\*](#TF1-1){ref-type="table-fn"}^ (wild)2IVS 1.52823Cd 8/92344Cd 41/424565HbE292[^4]

Hemoglobin profiling
--------------------

Mean hemoglobin concentration was 6.58±0.77 gm/dL in the HbS-β thalassemia group. In the thalassemia group, hemoglobin concentration was 5.62±1.93, 7.66±0.58 and 10.44±1.33 gm/dL in severe, moderate and mild anemia, respectively. Either hepatosplenomegaly or splenomegally alone was found in 28 (73.7%) subjects. Hemoglobin electrophoresis indicated that 12 (31.6%) out of 38 subjects harbored HbS. The overall distribution of hemoglobin fractions is listed in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

Table 2Sickle cell hemoglobin β-thalassemia. Clinical, hematologic and molecular data.N.Age\
(years)SexHbAHbFHbSHbA~2~OrganomegallyBlood\
transfusion\
frequency\
per yearHemoglobinβ-\
thalassemia\
mutationSeverity14M11.684.83.6Hepatosplenomegaly106IVS 1.5Severe212M11.683.94.5Splenomegaly87IVS 1.5Severe34F14.780.64.7Splenomegaly115.6IVS 1.5Severe48F17.577.25.3Splenomegaly96.6IVS 1.5Severe518F19.376.44.3Hepatosplenomegaly85.3IVS 1.5Severe66F22.573.14.4Splenomegaly77.8Cd 8/9Severe78M2372.44.6Mild hepatosplenomegaly66Cd 8/9Severe89F25.569.64.9Splenomegaly86.5IVS 1.5Severe90.6M7.212.377.33.2Hepatosplenomegaly36.6IVS 1.5Severe1015F141269.54.5Mild splenomegaly97.8IVS 1.5Severe1112F11.518.265.74.6Spelnomegaly, huge hepatomegaly76.8IVS 1.5Severe1216F17.128.949.44.6Splenomegally67IVS 1.5Severe[^5]

Table 3β-thalassemia. Clinical, hematologic and molecular data.N.Age\
(years)SexHbAHbFHbA~2~OrganomegallyBlood\
transfusion\
per yearHbβ-\
thalassemia\
mutationPhenotypeSeverity141M94.21.64.2NilNil11Cd 8/9HTMild21M22.972.84.3Hepatosplenomegaly96.5IVS 1.5HMSevere35M12.583.14.4Hepatosplenomegaly105.6IVS 1.5HMSevere48M28.567.14.4No (Splenectomy)66.5IVS 1.5HMSevere56M23.535.640.9Splenomegaly37IVS 1.5, HbECHTModerate65M6.788.64.7Splenomegaly85IVS 1.5HMSevere75F38.326.635.1HepatosplenomegalyNil10Cd 8/9, Hb ECHTMild85M13.282.93.9Hepatosplenomegaly115IVS 1.5HMSevere925F93.42.34.3NilNil11Cd 8/9HTMild1022F89.46.83.8NilNil10.6Cd 8/9HTMild1113M24.270.75.1Hepatosplenomegaly38HbE,Cd41/42CHTModerate1222F91.95.74.4NilNil10.4Cd 8/9HTMild1312M2.593.63.9Splenomegaly96IVS 1.5HMSevere145M6.988.84.3Splenomegaly125IVS 1.5HMSevere154F90.64.64.8NilNil11Cd 8/9HTMild169M7.2893.8Mild splenomegaly84IVS 1.5HMSevere178M8.787.14.2Nil49.8HbEHTMild183M590.74.3Hepatosplenomegaly116.4IVS 1.5HMSevere192M17.4784.6Mild splenomegaly67.3IVS 1.5,Cd 8/9CHTSevere204M2.8934.2Splenomegaly104.5IVS 1.5HMSevere2112F703.226.8SplenomegalyNil9.5IVS 1.5HTMild228M623.234.8Mild splenomegalyNil10HbEHTMild2329M6.23162.8NilNil10.5HbEHTMild2425F142561Splenomegaly28IVS 1.5,Cd41/42CHTModerate2536M94.71.53.8NilNil10.5Cd 8/9HTMild2632F942.33.7NilNil11Cd 8/9HTMild[^6]

Genotype-phenotype correlation
------------------------------

[Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show the genotypes of IVS1.5, HbE, Cd 8/9 and Cd 41/42 alone or in association with HbS and their phenotypes expressed in terms of clinical severity, *i.e. mild*, *moderate* and *severe*. IVS 1.5 associated genotype exhibited severe to moderate level phenotypes with IVS 1.5 homozygous alone (n=10) and IVS 1.5 with HbS (n=10) being the predominant association. HbE associated genotype presented minimal severity whereas Cd 8/9 associated genotype showed moderate severity.

Discussion {#S4}
==========

The present study confirmed distribution of β-thalassemia along with a genotype-phenotype correlation in an Indian population coexistent with *HbS* gene and high malarial incidence. Besides presence of other mutations, the present study demonstrated IVS 1.5 mutation as the predominant genotype (63%) in this population from Western Orissa, India. This is comparable with earlier findings.^[@R1],[@R17]^ This mutation, however, was largely associated with HbS, presenting severe thalassemic phenotypic expression in the study subjects ([Table 2](#T2){ref-type="table"}). Although a high rate of organomegaly was seen among the study subjects, an early start of transfusion could have prevented hypersplenism and red cell sensitization. The second major mutation found in Indo-Asians, *i.e.* IVS1.1, was not detected in this population; a rare observation in contrast to other parts of India,^[@R1]^ but in agreement with a recent report.^[@R11]^

With respect to β-thalassemia, HbE and HbS, aberrant heterosis in hemoglobinopathies was demonstrated in an earlier study,^[@R18]^ which highlighted co-inheritance of these genes seen earlier in southern and western Orissa. Though small in size, our study throws some light on a genotype-phenotype correlation and therefore on the diagnostic capacity of associative genotypes of β-tha-lassemia mutations ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). This may serve as a tool to predict clinical severity if detected in early life. The correlation can add to the existing knowledge to widen our understanding of the varied clinical presentation, phenotypic diversity and genotypic heterogeneity. This will help early intervention on patients at high risk and promote prevention by genetic counseling. Our data suggest that prediction of mild phenotypes may avoid unnecessary transfusion.^[@R17]^ We believe that a prenatal diagnosis plan, or at least newborn screening for molecular markers, can lead to better outcomes in developing countries with thalassemia endemicity.
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